Scarica l'app Stockscreener
4.35
4.61%
-0.21
Dopo l'orario di chiusura:
4.43
0.08
+1.84%
Precedente Chiudi:
$4.56
Aprire:
$4.49
Volume 24 ore:
3.74M
Relative Volume:
0.40
Capitalizzazione di mercato:
$339.54M
Reddito:
-
Utile/perdita netta:
$-209.96M
Rapporto P/E:
-1.3766
EPS:
-3.16
Flusso di cassa netto:
$-176.27M
1 W Prestazione:
-6.45%
1M Prestazione:
-24.08%
6M Prestazione:
-42.08%
1 anno Prestazione:
-59.23%
Intervallo 1D:
$4.295
$4.515
Intervallo di 1 settimana:
$4.295
$4.95
Portata 52W:
$2.68
$17.00
Replimune Group Inc Stock (REPL) Company Profile
Nome
Replimune Group Inc
Settore
Industria
Telefono
(781) 222-9600
Indirizzo
500 UNICORN PARK, WOBURN, MA
Confronta REPL con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
REPL
Replimune Group Inc
|
4.35 | 353.59M | 0 | -209.96M | -176.27M | -3.16 |
|
VRTX
Vertex Pharmaceuticals Inc
|
412.22 | 104.45B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
469.36 | 60.95B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
572.60 | 59.11B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
812.95 | 49.23B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
320.94 | 35.92B | 4.56B | -176.77M | 225.30M | -1.7177 |
Replimune Group Inc Stock (REPL) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-09-19 | Downgrade | JP Morgan | Neutral → Underweight |
| 2025-07-30 | Aggiornamento | Cantor Fitzgerald | Neutral → Overweight |
| 2025-07-23 | Downgrade | BMO Capital Markets | Outperform → Underperform |
| 2025-07-23 | Downgrade | Barclays | Overweight → Equal Weight |
| 2025-07-23 | Downgrade | H.C. Wainwright | Buy → Neutral |
| 2025-07-22 | Downgrade | JP Morgan | Overweight → Neutral |
| 2025-07-22 | Downgrade | Leerink Partners | Outperform → Market Perform |
| 2025-07-22 | Downgrade | Piper Sandler | Overweight → Neutral |
| 2025-07-22 | Downgrade | Wedbush | Outperform → Neutral |
| 2025-06-20 | Iniziato | Cantor Fitzgerald | Overweight |
| 2024-08-28 | Iniziato | ROTH MKM | Buy |
| 2023-04-17 | Ripresa | Piper Sandler | Overweight |
| 2021-11-19 | Iniziato | Piper Sandler | Overweight |
| 2021-10-15 | Ripresa | BTIG Research | Buy |
| 2020-11-17 | Iniziato | BTIG Research | Buy |
| 2020-11-02 | Iniziato | Jefferies | Buy |
| 2020-10-15 | Aggiornamento | H.C. Wainwright | Neutral → Buy |
| 2020-07-01 | Downgrade | H.C. Wainwright | Buy → Neutral |
| 2020-05-05 | Iniziato | Barclays | Overweight |
| 2019-09-04 | Iniziato | ROTH Capital | Buy |
| 2019-07-23 | Iniziato | Chardan Capital Markets | Buy |
| 2019-07-12 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2019-07-08 | Iniziato | H.C. Wainwright | Buy |
| 2019-04-25 | Iniziato | Wedbush | Outperform |
| 2019-01-23 | Downgrade | JP Morgan | Overweight → Neutral |
| 2018-08-14 | Iniziato | JP Morgan | Overweight |
| 2018-08-14 | Iniziato | Leerink Partners | Outperform |
Mostra tutto
Replimune Group Inc Borsa (REPL) Ultime notizie
How to build a custom watchlist for Replimune Group Inc.2025 Price Targets & Safe Entry Point Identification - newser.com
Will earnings trigger a reversal in Replimune Group Inc.2025 Price Momentum & Weekly High Potential Alerts - newser.com
How Replimune Group Inc. stock compares to growth peersStop Loss & Free AI Powered Buy and Sell Recommendations - newser.com
Why Replimune Group Inc. is moving todayMarket Trend Review & Fast Exit Strategy with Risk Control - newser.com
Real time social sentiment graph for Replimune Group Inc.Earnings Performance Report & Real-Time Chart Breakout Alerts - newser.com
Forecasting Replimune Group Inc. price range with options data2025 Technical Patterns & Risk Managed Investment Signals - newser.com
How to use a screener to detect Replimune Group Inc. breakoutsInsider Selling & Technical Entry and Exit Tips - newser.com
Will Replimune Group Inc. stock go up soon2025 Dividend Review & Technical Confirmation Trade Alerts - newser.com
Tools to assess Replimune Group Inc.’s risk profileMarket Risk Analysis & Weekly High Potential Stock Alerts - newser.com
Will a bounce in Replimune Group Inc. offer an exit2025 Pullback Review & Capital Efficient Trade Techniques - newser.com
Replimune’s SWOT analysis: oncology biotech stock faces FDA hurdles By Investing.com - Investing.com South Africa
Replimune’s SWOT analysis: oncology biotech stock faces FDA hurdles - Investing.com
REPLIMUNE ALERT: Bragar Eagel & Squire, P.C. is - GlobeNewswire
Published on: 2025-10-05 07:01:13 - newser.com
What does recent volatility data suggest for Replimune Group Inc.2025 Investor Takeaways & Growth Focused Stock Pick Reports - newser.com
Why retail investors pile into Replimune Group Inc. stock2025 EndofYear Setup & Free Fast Gain Swing Trade Alerts - newser.com
Published on: 2025-10-03 06:54:08 - newser.com
Replimune Group, Inc. (NASDAQ:REPL) Receives Average Rating of "Hold" from Analysts - MarketBeat
Strategies to average down on Replimune Group Inc.2025 Risk Factors & AI Powered Market Entry Strategies - newser.com
Will Replimune Group Inc. stock sustain high P E ratios2025 Price Action Summary & Momentum Based Trading Ideas - newser.com
Replimune Faces Big Swings After FDA Setback And Cash Concerns - Finimize
Join the Replimune Group (REPL) Securities Fraud Lawsuit Investigation - Claim Depot
REPL Stock Plunges 54% in 3 Months After FDA Rejects Skin Cancer Drug - TradingView
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Replimune Group, Inc. of Class Action Lawsuit and Upcoming DeadlinesREPL - WV News
Investigation announced for Long-Term Investors in shares - openPR.com
REPLIMUNE FINAL DEADLINE ALERT: Bragar Eagel & Squire, P.C. - GlobeNewswire
FINAL DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Replimune - FinancialContent
Replimune’s SWOT analysis: biotech stock faces FDA hurdles amid sector optimism By Investing.com - Investing.com South Africa
Recover Investment Losses: Levi & Korsinsky Files Class Action Against Replimune Group, Inc. (REPL) - ACCESS Newswire
Replimune’s SWOT analysis: biotech stock faces FDA hurdles amid sector optimism - Investing.com
REPL Deadline: REPL Investors with Losses in Excess of $100K Have Opportunity to Lead Replimune Group, Inc. Securities Lawsuit Filed by The Rosen Law Firm - PR Newswire
Replimune Group, Inc. Securities Fraud Class Action Lawsuit Pend - GuruFocus
Replimune Group, Inc. Securities Fraud Class Action Lawsuit Pending: Contact The Gross Law Firm Before September 22, 2025 to Discuss Your RightsREPL - WV News
Replimune Group Inc Azioni (REPL) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Replimune Group Inc Azioni (REPL) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Astley-Sparke Philip | Director |
May 20 '25 |
Sale |
8.06 |
32,279 |
260,169 |
1,405,071 |
| Xynos Konstantinos | Chief Medical Officer |
May 20 '25 |
Sale |
8.06 |
7,952 |
64,093 |
146,933 |
| Schwendenman Andrew | Chief Accounting Officer |
May 20 '25 |
Sale |
8.05 |
3,287 |
26,460 |
68,284 |
| Patel Sushil | Chief Executive Officer |
May 20 '25 |
Sale |
8.06 |
25,105 |
202,346 |
343,576 |
| Hill Emily Luisa | Chief Financial Officer |
May 20 '25 |
Sale |
8.05 |
2,535 |
20,407 |
143,522 |
| Sarchi Christopher | Chief Commercial Officer |
May 20 '25 |
Sale |
8.05 |
3,749 |
30,179 |
128,296 |
| Patel Sushil | Chief Executive Officer |
Dec 16 '24 |
Sale |
12.42 |
10,000 |
124,200 |
202,014 |
5.15%
1.45%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):